• Users Online: 38
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Archives Submit article Instructions Referee Resource Subscribe
Year : 2021  |  Volume : 8  |  Issue : 2  |  Page : 185-187

Favorable outcome of r-FSH treatment in male with homozygous Ser680ASN variant in FSHR gene: a case report demonstrating pharmacogenomic implication in male infertility

1 GeneTech, Hyderabad, India
2 Genesis Fertility and Laparoscopy Centre, Hyderabad, India

Correspondence Address:
Dr. Narmada Katakam
Genesis Fertility and Laparoscopy Centre, 10-01-80/1/2, Sai Venkateshwara Hospital, Kharmaghat, 500079 Telangana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/fsr.fsr_42_21

Rights and Permissions

Treatment of impaired spermatogenesis with recombinant follicle-stimulating hormone (r-FSH) has heterogenous response among patients. FSH receptor (FSHR) gene polymorphisms are known to be associated with male infertility with varied phenotype presentation. The presence of Serine 680 Asparagine (Ser680Asn) polymorphism is also linked to response to r-FSH when treating impaired spermatogenesis. We present a case of an Indian male with severe oligoasthenoteratozoospermia carrying homozygous Asn680Asn FSHR genotype, who responded favorably to r-FSH treatment, demonstrating significant improvement in seminal parameters and reduction of sperm DNA fragmentation index. Ser680Asn polymorphism of FSHR gene may serve as a clinically useful pharmacogenomic marker in identification of good responders to r-FSH treatment.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded60    
    Comments [Add]    

Recommend this journal